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Abstract: Nuclear receptors (NRs) play a key role in regulating virtually all body functions,
thus maintaining a healthy operating body with all its complex systems. Recently, gut microbiota
emerged as major factor contributing to the health of the whole organism. Enteric bacteria
have multiple ways to influence their host and several of them involve communication with
the brain. Mounting evidence of cooperation between gut flora and NRs is already available.
However, the full potential of the microbiota interconnection with NRs remains to be uncovered.
Herewith, we present the current state of knowledge on the multifaceted roles of NRs in the enteric
microbiota–gut–brain axis.
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1. Introduction
Nuclear receptors (NRs) and microbiota are two factors that together have a great impact on
all body functions. With the cloning of the first NRs in the 1980s, a great era of NR research begun.
The progressive discovery of the 48, 49 and 47 NRs in humans, mice and rats, respectively, and their
essential role in development, metabolism, homeostasis by directing virtually each single process in
these organisms, powered abundance of prospective research in this new field [1]. The prosperity of
NR research partially overlapped with increasing interest in the gut microbiota and its recognized
major regulatory function. An extraordinary profusion of microbiota research at the beginning of 21st
century changed our perception of gut bacteria from symbiotic organisms to forming a functional
“organ” modulating the host’s physiological and psychological health. Within the last years, research
in the field of microbiota gradually progressed from studies based on correlations between microbiota
composition and diseases (e.g., autism, obesity, metabolic and autoimmune diseases) to tracking
molecular pathways of interactions between specific bacterial strains, their metabolites and the
host. What we have learned so far is that gut microbiota is characterized by its high variability
in composition between different hosts, which is induced by multiple factors including childbirth
delivery, gender, life style, diet, age, the individual’s immune system, immunization, pharmacological
interventions, antibiotic treatments, contacts with other carriers of bacteria, length of exposure to factors
affecting bacterial composition, and geographical location [2–5]. Moreover, metabolites produced by
the gut flora itself also influence microbial communities in the gut, modulating their composition,
maintaining their optimal population size and protecting them from colonization by pathogens
through the production of bacteriocins [6]. Recently, it has been shown that the human gut microbiota
composition is influenced more by environmental factors than by the host’s genome. In fact, over 20% of
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inter-person microbiota variability is associated with factors related to diet, drugs and anthropometric
characteristics [7]. Based on the current state of research, we can conclude that: (1) the gut microbiota
is a complex and dynamic part of the body; (2) it is impossible to define a single and proper healthy
gut bacteria composition that would fit all due to highly individual external and innate factors shaping
distinct gut microbiota. Therefore, trying to compare and evaluate the determinants of microbiota
composition is a complex task. Moreover, studies in germ-free (GF) mice have shown that the gut
bacteria as an “organ” is not indispensable to live and thrive, at least in a laboratory environment.
However, the regulatory function of the microbiota with specific roles in gut, brain and whole organism
development and maintenance definitely represents an evolutionary benefit. During the long natural
history of the symbiosis between host and microbiota, resident gut bacteria developed multiple ways
of communicating with their host including with its central nervous system (CNS), which resulted
in the development of a key microbiota–gut–brain axis. The aim of this article is to review existing
evidence of the involvement of NRs in the interaction between host and gut microbiota, particularly in
the context of the gut–brain axis.
2. Gut–Brain Axis
By now, the interaction between the gut microbiota and the brain is an evidence-based fact.
Data suggest that the gut microbiota can affect physiological, behavioral and cognitive functions
of the brain [8–12]. Bidirectional signaling in the enteric microbiota–gut–brain axis is regulated at
neural, hormonal, and immunological levels and includes the CNS, neuroendocrine and neuroimmune
systems, the enteric and autonomic (sympathetic and parasympathetic branches) nervous system,
and intestinal microbiota factors. Visceral signals are transmitted directly to the CNS via afferent fibers
or indirectly by the blood circulation. Response signals from the CNS are mediated via efferent fibers
to the smooth muscles of the gastrointestinal (GI) tract, thereby influencing its motility and secretory
functions, which modify the environment in which the bacteria reside [12–15]. Host mental state,
especially under stress, has long-term effects on gut flora [16–18]. Stress increases gut permeability
and modulates growth of both non-pathogenic and pathogenic bacteria via the effects of dopamine,
adrenaline and noradrenaline produced by the host [19–26]. Importantly, adrenaline and noradrenaline
also modulate the expression of bacterial virulence genes [26,27].
As mentioned above, gut–brain signaling works both ways; thus, signals sent by resident bacteria
affect the whole body. The GI flora secrete an abundance of microbe-associated molecular patterns
(MAMPs) and bioactive metabolites such as bacteriocins, secondary bile acids (BA), choline and
short chain fatty acids (SCFAs). SCFAs are derived from the fermentation of polysaccharides and
influence the colon epithelium locally, but also enter the blood circulation and modulate the host’s
incretin production and energy balance [28]. By regulating the levels of satiety and hunger hormones,
including ghrelin [29,30], leptin [29,31–33], insulin [34], somatostatin [35], peptide YY (PYY) [30] and
glucagon-like protein-1 (GLP-1) [36,37], bacteria affect the host’s gut motility, nutrients absorption,
glucose tolerance, food cravings and hunger. Stunningly, gut flora may impact the levels of hunger
hormones by influencing the production of autoantibodies against peptide hormones involved in
appetite control [38]. Bacterial colonization of the intestine has a major role in post-natal development
and maturation of the endocrine, immune and nervous systems and affects the host’s physiological and
psychological health [8,39–45]. Enteric microbiota also regulates levels of sex hormones; transferring
the gut microbiota of male mice to females causes an elevation in testosterone levels and induces
metabolomic changes in recipient females [46]. Commensal flora itself is capable of synthesizing
and releasing many neurotransmitters and neuromodulators, or inducing enteroendocrine cells to
synthetize and release neuropeptides, thereby affecting the host’s behavior and stress levels. Bacteria
play a critical role in the production of free adrenaline in the gut lumen [47] and Escherichia, Bacillus
and Saccharomyces spp. can generate noradrenaline [48,49]. Furthermore, the microbiota affects the
hippocampus and amygdala levels of brain-derived neurotrophic factor (BDNF), a key neurotrophin
involved in neuronal growth and survival [42]. Lactobacillus and Bifidobacterium species can synthetize
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γ-aminobutyric acid (GABA), while Lactobacillus rhamnosus (JB-1) induces region-dependent alterations
in GABA(B1b) and GABA(Aα2) receptors in various parts of the brain [45,48,49]. Importantly,
vagotomized mice do not display the neurochemical and behavioral effects of L. rhamnosus (JB-1),
thus implicating the vagus nerve in the direct communication between bacteria and the brain [45].
Alterations in central GABA receptor expression are implicated in the pathogenesis of anxiety and
depression, which are highly comorbid with functional bowel disorders. Moreover, Bacillus can
produce dopamine, Lactobacillus can generate acetylcholine, and Candida, Streptococcus, Escherichia
and Enterococcus spp. synthetize serotonin (5-HT) [48,49]. 5-HT is a key regulator of GI motility and
secretion but also a modulator of depression and anxiety-like behavior. Approximately 95% of 5-HT in
the body is compartmentalized in the gut, predominantly in enterochromaffin cells of the mucosa and
in nerve terminals of the enteric nervous system. The presence of specific strains of bacteria or the
GF status in mice modulate 5-HT production by the enterochromaffin cells, which affects circulating
levels of 5-HT and tryptophan, a 5-HT precursor [50–53]. Interestingly, the delivery of the probiotics
Bifidobacterium infantis 35624, which results in an elevation in plasma tryptophan, has been suggested
as a promising anti-depressive therapy [53]. Thus, the continuous dialog between the GI flora and
brain—regulating parts of postnatal development, metabolism and daily body functioning—is essential
for a healthy brain and gut.
3. Nuclear Receptors
NRs together form a superfamily of proteins that function as transcription factors. In principle,
their activation requires the binding of ligands, which results in increased affinity towards NR-response
elements in the regulatory region of target genes leading to changes in their expression activity.
Multiple NRs are expressed in the GI tract, and several microbe-produced metabolites act as ligands
of NRs. Thereby, the activity of NRs may be affected by nutrient- and microbiota-derived ligands.
Gut bacteria secrete metabolites including indole derivatives, hormones and secondary BAs, which act
as natural ligands for the host’s NRs [54]. Thus, microbial metabolites influence the host by regulating
gene expression that modulates biological effects. This interactive system allows a direct influence of
the microbiota on the host’s physiology and, therefore, it can have control over the health or disease
status of the host.
3.1. PPARs
Peroxisome proliferator activated receptors (PPARs) are a sub-family of ligand-activated nuclear
receptors, which consists of three isotypes; PPARα (NR1C1), PPARβ/δ (NR1C2) and PPARγ (NR1C3),
each produced by a separate gene [55]. PPARs are collectively involved in the control of energy
metabolism, inflammatory and immune responses. Natural ligands of PPARs include fatty acids (FA),
eicosanoids and phospholipids [56,57]. Each PPAR isotype shows an individual pattern of expression
in the GI tract and exerts different functions [58]. However, all three of them are known for their
anti-inflammatory properties in the small intestine and colon. All PPARs mediate microbiota effects
and take part in the gut–brain axis signaling; however, the way they accomplish this function is distinct
(Figure 1). If their relation with the microbiota is mainly in the context of their anti-inflammatory
properties, signaling to the brain is mostly related to metabolism. These two functions are highly
interconnected in the GI tract as shown by our recent caloric restriction study in mice [59].
3.1.1. Peroxisome Proliferator Activated Receptor α
PPARα was initially identified as the molecular target of xenobiotics inducing peroxisome
proliferation in rodents [60]. PPARα is ubiquitously expressed and is particularly abundant in organs
with a high demand for catabolism of fatty acids [58]. The greatest expression of this isotype is in liver
and brown adipose tissue (BAT); the stomach and duodenum also show substantial levels of PPARα.
The expression of PPARα decreases along the GI tract with lowest levels in the colon [58].
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PPARα coordinates several aspects of metabolism by modulating the expression of genes
involved in peroxisomal and mitochondrial β-oxidation, FA transport, FA catabolism, ketogenesis
and gluconeogenesis [56]. PPARα is a nutritional status sensor and allows adaptation of the rates of
FA catabolism, lipogenesis and ketone body synthesis in response to nutritional status, particularly
during fasting [61–63]. During the fed state, PPARα synchronizes pathways of de novo lipid synthesis
to supply FAs for storage. In starvation, when the organism shifts to the mobilization of stored
FAs, PPARα switches its activity to promote cellular FA uptake and β-oxidation. Moreover, PPARα
stimulates the expression of rate-limiting enzymes of ketogenesis in the liver [64,65]. Importantly,
the role in ketone body synthesis is dependent on the stimulation of PPARα expression in the liver
by commensal gut microbiota [66]. Thus, microbiota-dependent PPARα activity modulates proper
metabolic adjustment to nutrient availability. Given these facts, it is not surprising that PPARα has
been identified as a major factor in the adjustment of metabolism during caloric restriction and daily
rhythms (rest/activity and fasting/feeding) [59,67–70]
PPARα is a major contributor to functional circadian rhythm by directly regulating transcription
of the important circadian genes Bmal1 and Rev-erbα [68,71], as well as modulating PER2 activity by
direct protein–protein interactions [67]. Additionally, PPARα itself is a target gene of BMAL1 and
CLOCK [68,72]. As a result, numerous genes involved in lipid and cholesterol metabolism, as well as
energy homeostasis, which are regulated by PPARα, display daily fluctuations in mouse liver [73,74].
It is noteworthy that PPARα, by mediating signals received from the microbiota via toll-like receptors
(TLR), contributes to both the circadian expression of genes in the intestine and intestinal corticosterone
production [75]. Thus, PPARα mediates signals from the GI flora, which impact the host’s physiology.
An additional link between PPARα and microbiota has been proposed recently [76]. PPARα was
identified as an important factor in the inflammatory response of the intestine to commensal microbiota.
According to the model proposed, PPARα regulates the expression of interleukin 22 (IL-22) and the
antimicrobial peptides Reg3β, Reg3γ, and calprotectin. In mice deficient in PPARα, commensal
dysbiosis in the gut occurs and results in an increased expression of inflammatory cytokines and
enhanced susceptibility to intestinal inflammation [76]. These findings comply with previous reports
associating intestinal PPARα with anti-inflammatory activity in the GI tract by preventing neutrophil
infiltration and protecting the intestine from colitis-induced permeability [77–80].
Even more interestingly, intestinal PPARα is involved in inducing satiety signals in the brain.
Oleoylethanolamide (OEA), an endogenous ligand of PPARα, is an endocannabinoid produced
by enterocytes in response to fat consumption [81]. Biosynthesis of OEA in the intestine requires
sympathetic innervation [82] and is modulated by BAs [83]. Accordingly, hepatic expression of PPARα
is stimulated by the farnesoid X receptor (FXR), which with the support of microbiota, controls BA
metabolism (for details see the further parts of this review below) [84]. Administration of OEA has an
anorectic effect by acting peripherally, prolonging eating latency or reducing meal size, depending on
the nutritional state, and leads to body weight reduction [81,85–87]. This effect is mediated by PPARα
activation in the proximal small intestine [81,88,89]. Surprisingly, intraperitoneal administration
of OEA acutely decreases energy expenditure, as well as ambulatory and spontaneous locomotor
activity [90]. It regulates lipid metabolism by activating PPARα to stimulate lipolysis, and decreases
neutral lipid content in hepatocytes as well as serum cholesterol and triglyceride levels [91]. OEA in
intestinal enterocytes engages afferent sensory fibers of the vagal nerve leading to increased expression
of c-fos in the nucleus solitary tract (NST) and the paraventricular nucleus (PVN) of the brainstem
and hypothalamus, respectively [91], which stimulates oxytocin secretion and promotes satiety [92].
Since enterocytes in the small intestine are the first cells responding to dietary fat intake by increasing
OEA production, OEA was suggested to serve as a gut-derived satiety factor [81].
3.1.2. Peroxisome Proliferator Activated Receptor β/δ
PPARβ/δ is ubiquitously expressed; nevertheless, its expression in the GI tract is very high
compared with other tissues. PPARβ/δ is abundant in the gut from the duodenum to the ileum,
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with lesser but still detectable expression in the colon [58]. Pparβ/δ is constitutively expressed in the
intestine, but inflammatory signals further stimulate its expression [93]. Intestinal PPARβ/δ induces
terminal differentiation of epithelial cells in the intestine and colon and is required for the differentiation
of Paneth cells [94–96]. Thus, PPARβ/δ is indirectly involved in secretion of antimicrobial peptides.
PPARβ/δ protects against dextran sulphate sodium (DSS)-induced colitis [97]; however, its role in
colon cancer has been controversial and conflicting results suggest that PPARβ/δ can either promote
or attenuate this disease [98].
When activated, intestinal PPARβ/δ promotes fatty acid oxidation in adipose tissue and skeletal
muscle, it improves dyslipidemia and stimulates overall energy expenditure thus protecting against
diet-induced obesity and insulin resistance [99]. It regulates plasma HDLc levels, influences expression
of genes involved in lipoprotein metabolism and stimulates postprandial GLP-1 production in
enteroendocrine L-cells, resulting in preservation of pancreas β-cell morphology and function thereby
increasing systemic insulin sensitivity [100]. However, the detailed mechanisms behind these beneficial
properties remain to be explored further. Thus, besides enhancing the satiety signal GLP-1, no other
link between intestinal PPARβ/δ and the CNS has been identified to date.
3.1.3. Peroxisome Proliferator Activated Receptor γ
PPARγ is mostly known for its insulin sensitizing properties and its role as a master regulator
of adipogenesis [101]. It modulates multiple processes, including cell proliferation, differentiation,
glucose and lipid metabolism, and inflammation [101–105]. PPARγ is highly expressed in adipocytes
and in the gut, and at lower levels in the pancreas, liver, kidney, and immune cells. In the GI tract, it is
present at a relatively high level in the proximal parts of the small intestine and gradually decreases
towards its distal parts. However, it is highly expressed in the proximal colon [58,106–108]. PPARγ
expression and activity are induced in the gut by multiple nutrients, most importantly by fatty acids and
their metabolites but also by glutamine, curcumin, capsaicin, ginsenosides and vitamin E, all of which
have been reported to exhibit anti-inflammatory properties [109]. Importantly, bacterial metabolites
and bacterial by-products, such as butyrate [110,111], propionate [112] and H2O2 [113] also stimulate
expression or activity of PPARγ. Presence of specific bacterial strains, such as Enterococcus faecalis,
Roseburia hominis, Roseburia intestinalis, Fusobacterium naviforme and Streptococcus salivarius influence
the phosphorylation of PPARγ and thereby its transcriptional activity [112,114,115]. Moreover, it has
been shown that the microbiota affects liver circadian rhythm by modulating the activity of PPARγ
expressed in liver [116]. Thus, there is a dynamic balance involving reciprocal interactions between
PPARγ and the gut microbiota, whereby PPARγ can both be activated by bacteria and regulate the
intestinal microbiota composition.
PPARγ has been identified as a promising therapeutic target in fighting colon cancer as it
reduces colorectal tumor development by decreasing cell proliferation [117–119], increasing cell
differentiation [117,120], inducing apoptosis [117,118,121–123], and inhibiting angiogenesis [124].
PPARγ agonists mitigate inflammatory bowel disease (IBD) symptoms, reduce inflammation, and are
effective in multiple models of ulcerative colitis as well as in Crohn’s disease [125–138]. PPARγ
acts as anti-inflammatory mediator by regulating multiple signaling pathways, including those
related to p53 [139], Bcl2 [121,123], c-Myc, [140], Cox-2 [123,141–143], Apc/B-catenin [144,145] and
NF-κB [121,143]. Notably, PPARγ is responsible for the selective killing of bacteria associated with
IBD and maintenance of innate antimicrobial immunity in the colon [146]. Hence, bacteria-mediated
stimulation of gene activity by PPARγ appears to have a protective role in the prevention of gut
inflammation and regulation of immune tolerance. Recently, we described a novel role of intestinal
PPARγ in long chain FA processing in the intestinal epithelium [147]. This is an original finding given
the fact that, so far, intestinal PPARγ has primarily been characterized in the context of inflammation
and cancerogenesis. Importantly, using an intestinal epithelium-specific PPARγ knockout mouse
model, we found a signaling mechanism between PPARγ expressed in intestinal epithelium and the
brain [148]. Intestinal PPARγ in mice submitted to caloric restriction or a diet low in sucrose regulates
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body adiposity by signaling via the sympathetic nerve system. Thus, activation of intestinal PPARγ by
bacterial metabolites or nutrients can impact adipose tissue via the nervous system.
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3.2. Farnesoid X Receptor (FXR)
BAs produced by the liver are stored in the gall bladder and secreted into the small intestine
where they contribute to the emulsification and solubilization of fats. Thus, they aid in the digestion
and absorption of lipids. The expression profile of genes involved in BA synthesis, conjugation,
and reabsorpti n is altered by the r sident gut mi robiota [149]. Certain secr te BAs undergo
biotransformation by the gut microbiota from primary to secondary BAs [150], and this process is
accompanied by a feedback mechanism of BAs on the microbiota composition [151,152]. Moreover,
secondary BAs, but also some of the primary BAs, can ct as ligands for the nuclear receptor
FXR (NR1H4), which is expressed in enterocytes throughout the small intestine and colon [153].
BA activation of FXR leads to subsequent alteration of the BA pool size via two FXR-dependent
feedback mechanisms of hepatic BA synthesis [154]. FXR regulates the transcription levels of critical
genes in BA synthesis, homeostasis, transport and metabolism [155] but also affects general lipid and
glucose metabolism [156], as well as hepatic autophagy [157,158]. Mice lacking FXR expression in the
intestine withstand diet-induced obesity (DIO), insulin resistance and non-alcoholic fatty liver disease,
and several studies associated FXR with sensitivity to metabolic diseases [149,159–162]. FXR knockout
may be mimicked by a treatment with tempol (4-hydroxy-2,2,6,6-tetramethyl-piperidine-N-oxyl) a
stable nitroxide which is a membrane-permeable, and metal-independent superoxide dismutase (SOD)
mimetic. Tempol decreased the Lactobacillus population in gut, accompanied by reduced activity of
bile salt hydrolase (BSH) normally exhibited by the bacteria. As a result, a potent antagonist of FXR,
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tauro-β-muricholic acid (T-β-MCA) accumulated in the intestine, demonstrating that the enteric flora
can modulate the activity of FXR [159]. Moreover, the gut microbiota has been shown to promote DIO
and stimulate adiposity via activation of the intestinal BA/FXR axis, which contributes to alteration
of the ceramide/SREBP1C/CIDEA pathway in the liver and disrupts lipid homeostasis [149,160].
Conversely, FXR may contribute to increased adiposity by modulating the composition of the gut
microbiota [149]. Thus, the tie between FXR and microbiota is tight and complex and, therefore,
difficult to dissect. However, it is sufficiently documented that targeting bacteria or BA composition
can result in changes of FXR activity and body weight.
A link was identified between the BAs in the gut and cystic breast tissue in humans [163,164].
The bile salt lithocholate originating from the intestine was found in aspirates of cyst fluid from the
breasts of women with fibrocystic disease at much higher concentrations than in the serum [163].
Additionally, BAs such as deoxycholic acid (DCA) have been shown to stimulate both the growth and
metastasis of breast cancer cells through FXR expressed in the breast cancer tissue [165], suggesting
that BAs may play a role in breast tumor carcinogenesis.
Among other genes, FXR binds a response element in the regulatory region of Fgf15 (a rodent
ortholog to human Fgf19) and directly regulates its transcription. FGF15 is produced in the distal small
intestine, and is secreted into the portal circulation to function as a postprandial hormone [166,167].
Its levels rise following a meal with a lag comparable to that of insulin. In contrast to other enterokines
(e.g., GLP-1, GIP), FGF15 does not affect insulin secretion but rather mimics insulin impact [167,168].
The peak of FGF15 occurs 90–120 min after the postprandial release of BAs, precedes the repression
of BA synthesis [167], and causes the gallbladder to refill with bile [169]. Secreted FGF15 circulates
to the liver, where it acts on two receptors: FGF-receptor 4 (FGFR4) and β-Klotho (KLB). This results
in the activation of the Ras–ERK–p90RSK pathway, which affects the expression of genes, such as
c-Fos, JunB, and c-Jun [168,170]. FGF15 inhibits BA synthesis in the liver by repressing the transcription
of the cholesterol 7α-hydroxylase gene (Cyp7a1), which encodes the first and rate-limiting enzyme
in the classic BA synthesis pathway [171]. FGF15 also stimulates hepatic protein and glycogen
synthesis [172], contributes to the regulation of systemic lipid and glucose metabolism [173] and
represses gluconeogenesis through a mechanism involving the dephosphorylation and inactivation of
the transcription factor CREB [174]. Importantly, according to the current state of knowledge FGF15
represents a key factor in the FXR–gut–brain axis connection. FGF15 secreted from the intestine
leads to activation of its receptors in hypothalamic AGRP/NPY neurons leading to reduction of
signaling by these neurons. This regulation promotes glucose tolerance presumably mediated by the
autonomic nervous system [175]. Thus, FGF15 can modulate metabolism by acting directly on the
brain, which is supported by the observation according to which intra-cerebro-ventricular injection
of FGF15 reduces 24 h food intake and body weight, and acutely improves glucose tolerance [176].
In ob/ob mice, FGF15 administered centrally increases glucose disposal via an insulin-independent
mechanism [177]. Remarkably, FGF15-triggered nerve signaling is required for longer-term weight
loss and glycemic effects while its activity in the liver and adipose tissue is not [178]. Notably,
expression of human FGF19-receptors 1 and 4 in the hypothalamus of obese rats is reduced by 60%
relative to lean animals [176]. It has been shown that intestinal PPARα affects FXR-FGF15 activity
and BA synthesis [179] and BA feedback inhibits PPARα activity [180]. Thus, we can speculate that
gut–brain communication involves the microbiota and at least two NR networks, in other words a
microbiota–PPARα–FXR–FGF15–gut–brain axis.
3.3. Vitamin D Receptor
Synthesis of vitamin D is initialized when UVB light triggers photochemical, non-enzymatic
conversion of 7-dehydrocholesterol to previtamin D3 in keratinocytes of the skin. Consecutively
previtamin D3 undergoes thermal isomerization to vitamin D3 (cholecalciferol). Following circulation
in the bloodstream, vitamin D3 is taken up by liver and modified to the prohormone calcifediol
(25-hydroxyvitamin D3, 25(OH)D3). Additionally, vitamin D2 or ergocalciferol, which can be provided
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by nutrition, including sources like fish, egg and mushrooms, serves as another precursor that may
be modified to calcifediol. Further conversion of calcifediol into calcitriol (1,25-dihydroxyvitamin D,
1,25(OH)2D) is executed by 1α-hydroxylase (CYP27B1) and takes place mostly in the kidneys.
Nonetheless, 1α-hydroxylase is also expressed in other tissues including colon, breast tissue and
immune cells [181–185]. Levels of vitamin D in the blood show a strong relationship with infection rates,
bone health, cancer prophylaxis and mortality [186–190]. Calcifediol and calcitriol serve as ligands for
the vitamin D receptor (VDR, NR1I1), the second being a more potent activator [191]. Additionally,
the secondary bile acid lithocholic acid, curcumin, γ-tocotrienol, and derivatives of essential fatty acids
also act as ligands of VDR [192,193]. Upon activation by ligands, VDR activates or represses expression
of its target genes. VDR is particularly important for the homeostasis of minerals by regulating
the intestinal uptake of calcium, iron, magnesium, zinc, copper and selenium. VDR also regulates
calcium reabsorption in kidneys and promotes bone calcification. Notably, VDR also facilitates
intestinal absorption of toxic elements like lead, aluminum, cadmium, cobalt and strontium [194].
VDR is expressed throughout the body with high levels in the intestine, colon, thyroid gland and
kidney. Its expression in the brain remains to be clarified as there are contradictory reports on this
subject [195–197]. Importantly, vitamin D can barely diffuse through the blood brain barrier (BBB) [198]
however, 1α-hydroxylase is expressed in the CNS [199,200] suggesting a role in the brain.
VDR plays an important role in the immune response, mediates signals from the microbiota
and translating them into appropriate inflammatory responses [201–203]. VDR influences the
expression of defensins, the antimicrobial function of Paneth cells and colonization of the GI tract
by bacteria [204–206]. Consequently, the microbiota of VDR knockout mice differs when compared
to wild type mice [207]. Intestine epithelium-specific VDR knockout mice are also more susceptible
to DSS-induced colitis [206]. The TLR pathway when activated by pathogen-associated membrane
patterns (PAMPs) of Mycobacterium tuberculosis stimulates VDR expression. In turn, VDR is necessary
for the generation of the antimicrobial peptides cathelicidins by monocytes-macrophages and the killing
of intracellular Mycobacterium tuberculosis [208,209]. Moreover, the probiotic Lactobacillus rhamnosus
strain GG and Lactobacillus plantarum trigger the expression and transcriptional activity of VDR and
thereby protect from Salmonella-induced colitis in a VDR-dependent way [210]. Reciprocally, microbiota
regulates local production of vitamin D3 in the colon by signaling through the TLR pathway [211].
VDR is a vital factor in brain development [212], neurotransmission [213], neuroprotection [214,215]
and immunomodulation [216,217]. Vitamin D deficiency has been linked with occurrence of
autism [218,219], schizophrenia [220–222], multiple sclerosis [223,224], Alzheimer’s and Parkinson’s
disease [225]. However, the putative mechanisms linking VDR to neurological diseases remain to be
unveiled. Moreover, a direct role of VDR in the gut–brain axis has not been established so far.
3.4. Xenobiotic Receptors
3.4.1. Aryl Hydrocarbon Receptor
Aryl hydrocarbon receptor (AHR) is not per se a member of the NR superfamily, although it shares
many characteristics with family members. AHR is a ligand-activated receptor expressed in many cell
types, including intestinal epithelial cells (IEC). AHR is mostly recognized as a molecule activated by
the xenobiotic 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD, also known as dioxin) [226,227]. However,
the list of its agonists is much longer and contains various groups of molecules including diet-derived
compounds (e.g., flavonoids, carotenoids, stilbenes) [228–230], metabolites of tryptophan produced
by the host, such as kynurenine (KYN) [231] or kynurenic acid (KYNA) [232], and by the microbiota
(indoles) [233,234]. Also, phenazine produced by Pseudomonas aeruginosa, and naphthoquinone
phthiocol from Mycobacterium tuberculosis bind to AHR, which triggers cytokine and chemokine
production [235]. Moreover, the bacterial metabolites SCFAs modulate AHR activity, however not
directly as ligands, but they stabilize and facilitate AHR actions [236]. Intestinal AHR affects the
differentiation and function of T cells, macrophages, and dendritic cells [237–244]. AHR expressed
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in CD11c+ cells modulates the development of intestinal epithelium and intestinal immunity [245]
thus, in turn it may modulate gut microbiota composition. Expression of AHR is attenuated in GF
mice and AHR seems to mediate the impact of microbiota on the host’s metabolic parameters. Hence,
AHR has been suggested to act as a mediator in the communication between the host and its gut
microbiota [246]. The most evident interaction between microbiota and AHR comes from a study on
the caspase recruitment domain family member 9 (CARD9). CARD9 promotes recovery from colitis
by stimulating interleukin (IL)-22 production. Hence, Card9−/− mice are more susceptible to colitis.
Interestingly, the Card9−/− mice-specific microbiota fails to metabolize tryptophan into compounds
acting as AHR ligands. Transfer of these bacteria to wild-type GF recipients increases their susceptibility
to colitis. Intestinal inflammation in these transfer recipients is attenuated after inoculation of the
mice with three Lactobacillus strains capable of metabolizing tryptophan or by treatment with an
AHR agonist [247]. Thereby, host expression of genes like Card9 affects the microbiota pool and this
regulation feeds back on the host’s health-status.
In the liver, PPARα and AHR affect the expression of a similar set of genes including Cd36,
Hmgcs2 [246,248], Cyp2B, Cyp3A, Cyp2C11 [249] and Fgf21 [65,250,251], indicating that there is an
interplay between these two factors, which has been investigated [249,252–254]. FGF21 has been
identified as the mediator of the metabolic benefit of AHR [251]. In turn, the impact of FGF21
on metabolism is partly mediated by PPARγ [255] creating a feed-forward loop as PPARγ also
induces FGF21 expression [256]. FGF21 stimulates the expression of genes involved in lipid oxidation,
ketogenesis and gluconeogenesis [65,257,258]. FGF21 improves insulin and leptin sensitivity and
lowers blood glucose levels by activating glucose uptake in adipocytes. Its administration results
in reduced body weight due to enhanced energy expenditure, fat oxidation and lipid excretion,
while reducing hepatic de novo lipogenesis and hepatosteatosis [251,259,260]. Similarly to FGF15,
the role of FGF21 in metabolism and body weight regulation seems to require mostly its central,
rather than peripheral signaling [178,261,262]. Along these lines, microbiota-stimulated AHR may
regulate metabolism via FGF21-mediated signaling to the CNS. Interestingly, in response to sugar
consumption, hepatic FGF21 is released and attenuates sugar-seeking behavior by targeting the
hypothalamic PVN [263,264]. Activation of FGF21 upon sugar uptake is mediated by hepatic PPARα
and carbohydrate-responsive element-binding protein (ChREBP) [263]. Beside affecting metabolism,
FGF21 regulates hydration by suppressing alcohol intake in favor of water consumption and this
activity is mediated in part by SIM1-positive neurons in the hypothalamus [265].
AHR is widely expressed in the CNS [266,267] and plays there a multitude of roles in cell
differentiation and maintenance. AHR-1, a Caenorhabditis elegans orthologue of AHR, is responsible
for the development, orientation, and axonal migration of AHR-1-expressing neurons [268].
AHR-1 impacts neural cell fate determination in C. elegans, particularly GABAergic neurons [269].
Dioxin-activated AHR plays a role in CNS development in zebrafish [270] and mice [271,272]. However,
expression of a constitutively active AHR in mice retards the development of interneurons in the
olfactory bulb [273]. Furthermore, both deletion or activation of AHR alters adult hippocampal
neurogenesis and impairs hippocampal-dependent contextual memory [274], suggesting a need
for a balanced AHR activity. AHR has been shown to affect several aspects of behavior and
neurodevelopmental illness in different study models [275,276]. AHR has been shown to decrease
blood brain barrier (BBB) permeability [277,278], while BBB permeability is increased in GF mice [279].
However, the mechanism behind is not clear as AHR is capable of activating occludin and claudin 1
and 4 [280], but on the other hand it inhibits connexin 43 [281], which is essential for BBB integrity [282].
This is probably another example of the dual role of AHR, which again underlines the importance of a
balanced activation of AHR. Moreover, AHR mediates anti-inflammatory effects on dendritic cells [283].
Ligand-activated microglial AHR exerts bi-directional effects on the regulation of LPS-induced
neuroinflammation as it can promote or inhibit inflammation [284,285]. Notably, in patients with
multiple sclerosis circulating levels of AHR agonists are decreased [286].
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The effects of AHR expressed in CNS can be modulated by the microbiota [286]. Astrocytes are
the most abundant glial cell population in the CNS, participating in diverse functions including
control of the BBB, regulation of metabolism, neuronal transmission, CNS development and
inflammation [287]. In experimental autoimmune encephalomyelitis (EAE), type 1 interferon (IFN-I)
signaling in astrocytes reduces disease scores and inflammation via AHR and the suppressor
of cytokine signaling 2 (SOCS2). EAE scores in mice increase following ampicillin treatment,
whereas dietary supplementation with the microbial metabolites of tryptophan (indoxyl-3-sulfate,
indole-3-propionic acid and indole-3-aldehyde)—which as mentioned above are AHR ligands—or
delivery of the bacterial enzyme tryptophanase reduces CNS inflammation in the antibiotic treated
mice. Thus, IFN-Is produced in the CNS functions in combination with bacterial metabolites of dietary
tryptophan to activate AHR signaling in astrocytes and suppress CNS inflammation [286].
3.4.2. Pregnane X Receptor
Pregnane X receptor (PXR, NR1I2) also known as the steroid and xenobiotic sensing nuclear
receptor (SXR) is a nuclear transcription factor often referred as the master regulator of xenobiotic
defense. PXR is involved in energy [288,289] as well as xenobiotic metabolism and it affects expression
of phase I and phase II enzymes as well as phase III transporters [290]. PXR is expressed in barrier
and excretory tissues, including intestine, liver, kidney and several regions of the brain [290–292] and
it is synthetized as various splice variants in different organs [292–294]. In the liver, the function of
PXR overlaps with that of FXR by regulating expression of a similar set of CYP proteins involved in
both detoxification and BA metabolism. Additionally, other PXR target genes that are involved in
xenobiotic metabolism also participate in BA metabolism [295]. In primary human hepatocytes, among
other factors PXR regulates AHR and its target genes Cyp1A1 and Cyp1A2 [296]. Similarly to AHR,
PXR is activated by microbial-specific metabolites of dietary tryptophan, and the indole derivative,
indole 3-propionate (IPA) [297], which is produced by Clostridium sporogenes [52]. The ligand binding
pocket of PXR has a relatively large volume capable of accommodating a variety of compounds.
Moreover, PXR has the capability to expand its binding pocket to allow for larger compounds thus,
various ligands are capable of its activation [298].
Secondary BAs, lithocholic acid (LCA) and its 3-keto metabolite (3-keto LCA), formed in the
intestine by bacteria are ligands of mouse and human PXR [295,299]. LCA is a particularly toxic BA
that causes cholestasis, a disease characterized by the impairment of bile flow and the accumulation of
BA and biliary toxins in the liver and serum [300]. Moreover, pregnenolone 16α-carbonitrile (PCN),
a ligand of PXR, blocks the hepatotoxicity and mortality caused by LCA exposure in rats [299,301].
Therefore, PXR, among other ligands, serves as a receptor of BA and upon activation coordinates the
xenobiotic response in the detoxification of BAs.
Single nucleotide polymorphisms in Pxr are associated with increased susceptibility for
developing IBD, Crohn’s disease and ulcerative colitis [302]. While PXR-deficient mice exhibit “leaky”
intestine symptoms [297], ligand-activated PXR prevents leaky gut and maintains the intestinal
epithelial barrier by stimulating the synthesis of junctional proteins, antagonizing TNF-α and TLR4,
inhibiting the cytokine-induced myosin light chain kinase (MLCK), and activating the c-Jun N-terminal
kinase 12 (JNK1/2) [291,297,303,304]. Rifaximin, an antimicrobial agent used in the treatment of IBD,
mediates its effects by increasing the expression of PXR. It has been shown to abrogate the DNA
binding of NF-κB caused by LPS, to reduce mRNA levels of IL-8, RANTES, MIP-3α and TNFα [305].
Chrysin, a naturally occurring flavonoid with anti-inflammation activity, prevents DSS-induced colitis,
an effect largely mediated by PXR [306]. Furthermore, the above mentioned PXR agonist, PCN,
attenuates the intestinal barrier dysfunction observed after DSS administration in mice [304].
Absence of PXR is associated with anxiety-like behavior and recognition memory impairment
in adult mice [307]. PXR knockout (KO) mice show decreased expression of tight junction protein
ZO1 in the cortex and cortical microvessels [307]. In another study, activation of hPXR in mice in vivo
tightened the BBB, reducing the delivery and central effect of administrated drugs. This effect is
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mediated by PXR-stimulated upregulation of P-glycoprotein, an ATP-driven drug export pump at
the BBB [308]. P-glycoprotein is the most prominent drug efflux transporter at the BBB and plays an
essential role in barrier function. Hence, most likely, similarly to AHR, microbiota derived-ligands
regulate PXR activity in CNS, thus affecting the BBB.
3.4.3. Constitutive Androstane Nuclear Receptor (CAR)
CAR (NR1I3) or constitutive androstane nuclear receptor, alike AHR and PXR, serves as a
xenosenor. CAR expression level is affected by various factors. It is induced on the level of expression
or activity by glucocorticoids (GC) [309], AHR [310], peroxisome proliferator-activated receptor γ
coactivator-1α (PGC-1α) [311] and repressed by factors like epidermal growth factor (EGF) [312],
TLR-2 signaling [313] and IL-1β [314]. Beside xenobiotics, CAR can be regulated by many endobiotics,
including many steroids (androstanes, estrogens, and progestins) [315,316]. Importantly, expression of
CAR in the intestine and in the liver depends on the presence of the microbiota [313,317]. CAR was
originally characterized as a transcriptional regulator whose activation is stimulated by phenobarbital
(PB) to stimulate the expression of CYP2B genes [318,319]. By now, the list of both the activators and
target genes of CAR has significantly expanded and shows a high overlap with the corresponding
list for PXR. These two NRs are often described together as both are expressed in organs like the
small intestine, colon and liver. They both react to chemical stresses and are crucial to initial ligand
recognition followed by subsequent jump-starting of xenobiotic metabolism. They work together
to ensure homeostasis of cholesterol, BAs, sterols, lipids, heme and other endogenous hydrophobic
molecules. Furthermore, the different splice variants of CAR, similarly to those of PXR, result in a
number of deleterious or altered effects on gene transactivation, coregulator recruitment, as well as
ligand binding [296,320–323]. Although CAR is less promiscuous than PXR, the smaller pocket size of
CAR creates a more stable ligand-bound complex than the one of PXR, resulting in better packing of
the AF-2 helix in the active conformation [324]. However, CAR is unique, relative to other NRs, in its
ability to maintain a constitutive activity in the absence of a bound ligand. This ability is also referred
to as an indirect activation, the exact mechanism of which remains to be elucidated [325,326]. In its
inactive form, CAR, just like PXR, is bound to heat shock protein 90 (Hsp90) in the cytoplasm [327].
Upon activation and heterodimerization with the retinoid X receptor (RXR) it stimulates target gene
expression in the cell nucleus [328]. A notable feature recently highlighted for CAR is that upon
ligand binding it can also undergo translocation to cell membrane, which could imply additional
non-genomic actions [329].
Notably, because CAR and PXR can be activated by the same ligands, upregulation of overlapping
sets of genes allows for coordinated clearance and detoxification of harmful compounds [296,330].
Importantly, some drugs inhibiting CAR are agonists of PXR, thus allowing detoxification to take
place even in the absence of one of the sensors. Together, the two NRs regulate expression of
phase I enzymes of xenobiotics metabolism including CYP3As [331,332], CYP2Bs [319,332–334],
and CYP2Cs [332,335,336]. They are capable of regulating approximately 90% of all phase II metabolic
enzymes as both are involved in the transcriptional control of UDP-glycosyltransferases (UGTs),
sulfotransferases (SULTs), glutathione-S-transferases (GSTs), acetyltransferases [324,337] as well as the
drug transporters OATP1 and MDR1 involved in phase III detoxification [332].
CAR has also been linked to energy metabolism as its activation results in inhibition of
lipogenesis, FA synthesis, and gluconeogenesis, as well as the increase of energy expenditure in
BAT [338]. Long-term CAR activation improves glucose homeostasis and insulin sensitivity [339].
These effects are achieved by suppressing the expression of phosphoenolpyruvate carboxykinase
(PEPCK), glucose-6-phosphatase (G6Pase) [339,340], and sterol regulatory element-binding protein
1c (SREBP1c) [341]. A very similar phenotype has been associated with PXR activation [288,289,342].
Moreover, fasting and caloric restriction induce CAR expression, which in turn coordinates an
adaptive response by slowing down energy expenditure. Consequently, CAR KO animals are
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unable to accomplish the metabolic adjustment and lose more weight during caloric restriction
interventions [343].
In the intestine, CAR gene expression is reduced in intestinal mucosal biopsies obtained from
patients suffering from Crohn’s disease or ulcerative colitis with active mild or moderate inflammation,
as well as in tissues isolated from colitic mice. Selective activation of CAR enhances wound healing
in IEC monolayers in culture, an effect driven by enhanced cell migration. Finally, inhibition of
CAR delays mucosal healing after the induction of experimental colitis, while its pharmacological
activation accelerates recovery [344]. Thus, by affecting colonic health, CAR alters the natural milieu
of the microbiota.
Notably, as shown by using null mice, CAR affects structural factors in the brain and the behavior
of mice. These CAR-null animals show impairment in recognition memory and increased anxiety-like
behavior, which is accompanied by neuronal and structural defects in the hippocampus and cortical
area. Moreover, expression of the tight junction protein ZO-1 is reduced in cortical and hippocampal
microvessels of the animals. Accordingly, peripheral injection of the neurotoxin kainic acid provokes a
rapid onset of convulsions in CAR-null mice as compared to WT mice, indicating increased vascular
permeability and susceptibility of these mice to neurotoxins [345].
In conclusion, gut flora modulates CAR activity, and CAR feeds back by reducing and promoting
gut inflammation and healing, respectively. There is no evidence of direct gut–brain communication
involving CAR. However, the CAR–microbiota interaction in gut, CAR’s role in the brain, and the
importance of other xenobiotic receptors in gut–brain signaling provide a basis to speculate on a
potential CAR-mediated signaling between the GI tract and CNS.
It seems that all of the xenobiotic receptors–AHR, PXR and CAR—interact with microbiota,
and are required for the proper functioning of the brain (Figure 2) [346,347]. Importantly, these NRs
are interconnected and show high level of coordination, and thus future research may show that they
embody an essential pathway in gut–brain communication.
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Figure 2. Xenobiotic receptors in the gut-brain axis. Bacterial metabolites, mainly indole and bile
acids (BA) serve as ligands for xenobiotic receptors. These NRs play multifold roles in the brain by
affecting the CNS development, permeability of the blood-brain barrier (BBB), memory and anxiety.
Broad blue arrows illustrate the action of both PXR (pregnane X receptor) and CAR (constitutive
androstane nuclear receptor), narrow blue arrows the actions of single factors, black arrows indicate
bacteria-derived signals and the red arrow the impact of GI inflammation on the microbiota.
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3.5. Steroid Receptors
3.5.1. Glucocorticoid Receptor
The main steroids of the adrenal cortex are mineralocorticoids (MCs), glucocorticoids (GCs
in humans mainly cortisol and in rodents mainly corticosterone) and the adrenal androgens.
GCs are synthesized and released as a result of stress, but also in a daily oscillating manner [348].
The circadian release of GC can be maintained regardless of sleep pattern, light stimulation and
rhythm of caloric intake [349,350]. Coordinated release of GCs, mineralocorticoids and catecholamines
by the adrenal glands in response to stress is governed by the hypothalamic–pituitary–adrenal
(HPA) axis, also referred to as the “stress axis”. Signals such as daylight promote the release of
corticotrophin-releasing hormone (CRH) from the hypothalamus. CRH then stimulates the production
of the adrenocorticotropic hormone (ACTH) in the pituitary, which in turn, initiates release of GC from
the adrenal cortex to blood. As GC levels rise, a negative feedback loop is engaged that reduces both
CRH and ACTH expression and secretion. This feedback mechanism regulates the magnitude and
duration of GC release [351].
Although endogenous GCs are predominantly produced by the adrenal glands, there is evidence
for extraadrenal GCs synthesis in the skin [352], thymus [353,354], vascular wall [355], lungs [356],
brain [357] as well as IEC [358]. More specifically, liver receptor homologue-1 (LRH-1) in the cells of the
crypt region of the intestinal epithelial layer promotes the expression of steroidogenic enzymes and the
synthesis of corticosterone [358]. Additionally, immune stress and T cell activation are also stimulators
of intestinal expression of the steroidogenic enzymes required for GC synthesis [359]. Importantly,
the microbiota contributes to the production of corticosterone in the intestine [75] and influences the
intracellular activity of GCs [360].
GCs are essential primary stress response hormones necessary for regulating numerous
physiological processes in order to maintain homeostasis, and they reduce inflammation. Overall,
their major effect on glucose homeostasis is to secure plasma glucose levels for brain during stress [361].
However, GCs also mediate multiple other physiological processes, including metabolic homeostasis,
skeletal growth, cardiovascular function, reproduction, and cognition [362–364]. Synthetic derivatives
of these hormones serve in the clinics as a standard treatment for inflammatory diseases, autoimmune
disorders and hematologic cancers. Depending on the concentration of GCs, different receptor
responses are triggered. Basal plasma levels of GCs are mediated via the mineralocorticoid receptors
(MRs, NR3C2) (see below), while elevated, stress or circadian rhythm-triggered GCs activate the
glucocorticoid receptors (GRs, NR3C1) [365,366]. The GR is expressed in almost every cell in the
body and in multiple brain regions including the cerebral cortex, olfactory cortex, hippocampal
formation, amygdala, septal region, dorsal thalamus, hypothalamus, trapezoid body, cerebellar cortex,
locus coeruleus and dorsal raphe nucleus [367,368]. GR is encoded in a single gene, however, there are
multiple GR protein isoforms. Alternative splicing of the 3′-end of the GR pre-mRNA produces
GRα, GRβ and GRγ [369–371]. Moreover, alternative translation initiation from the single GRα
mRNA transcript produces an additional eight diverse GRα proteins [372]. This substantial group of
functionally distinct receptor subtypes undergoes various posttranslational modifications that further
diversifies their signaling properties [373–375]. In the cytoplasm, GC-activated GR is released from
a multiprotein complex composed of HSPs and immunophilins of the FK506 family [376,377] then
translocates to the cell nucleus and modulates gene transcription via the following three mechanisms:
GC receptor response element (GRE)-mediated direct transactivation; inverted repeat GREs (IR
nGREs)-mediated direct transrepression; and tethered indirect transrepression [378–384]. The capacity
of the GR to function as a transcriptional activator or repressor is determined by several polymorphisms
in the GR gene [385]. GR can also modulate mRNA splicing [386] and mRNA stability [387] as well
as microRNA expression and processing [388]. MR and GR can create homodimers or heterodimers
acquiring new transcriptional properties [389,390]. Moreover, GR exhibits nongenomic signaling
by direct protein–protein interactions that result in rapid cellular responses occurring within a few
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seconds to minutes, which involve the signaling cascade of various kinases and do not require changes
in gene expression [380,391–393]. The various GR forms and their signaling modes generate pleiotropic
effects in distinct tissues [394,395].
GCs and circadian rhythm factors are reciprocally regulated. The central circadian clock in
the suprachiasmatic nucleus (SCN) of the hypothalamus entrained by light received by the retina
orchestrates diurnal rhythmic oscillation of circulating GCs by influencing the activity of the HPA
axis [396,397]. Additionally, the circadian rhythm core transcription factor heterodimer Clock-Bmal1
acetylates GR in peripheral tissues and represses its transcriptional activity in a circadian pattern
that is opposite to the GR activation pattern by the HPA axis [398]. In return, the HPA axis,
through the GR, drives circadian and ultradian bursts of transcriptional activity of the circadian
rhythm regulators (Per 1, DBP) and adjusts the rhythmicity of the peripheral clocks in response to
stressors [396,399]. Thus, the circadian rhythm of the peripheral clocks may become phase-shifted
by GCs. Disruption of GR expression periodicity is associated with disease states characterized
by GC resistance or sensitivity [400]. Moreover, cortisol-driven circadian and ultradian patterns
of transcriptional activity of the Clock and Per genes is disrupted in major depressive disorders,
bipolar disorder, and stress-related GI and immune disorders [401]. Furthermore, intestinal processes
including nutrient absorption, cell proliferation, intestinal motility, metabolic activities as well as
intestinal GC production are rhythmically regulated in a circadian manner [75,402]. Clock genes are
expressed along the GI tract, their mRNA levels increase from the duodenum onwards and show
highest levels in the colon. Similar to other organs, the clock genes in the jejunum and colon show a
circadian rhythm of expression [403–405]. Moreover, the intestinal microbiota exhibits endogenous
circadian rhythmicity that is partly synchronized with the host’s dietary rhythm [406–408]. Remarkably,
gut microbiota-derived MAMPs, acting via TLR, regulate circadian clock genes and PPARα and thereby
modulate the production of intestinal corticosterone [75]. Moreover, microbial cycles disturbed by a
high-fat diet results in disruption of the central and liver clocks [407].
GR regulates multiple systems including the nervous, cardiovascular, musculoskeletal, immune,
respiratory, reproductive, adipose and hepatic systems. It adjusts blood glucose levels by stimulating
hepatic gluconeogenesis via direct induction of the PEPCK gene [409]. It suppresses bone formation
by a number of mechanisms, including reduction of osteoblast differentiation [410], induction
of osteoblast apoptosis [411], and stimulation of bone resorbing osteoclasts [412]. In adipocytes,
it increases adipogenesis, alters adipokine production, reduces glucose metabolism and lipogenesis
under basal or fasted conditions, while it stimulates lipogenesis in the fed state [413]. GCs extinguish
inflammation and this is in part executed by GR’s ability to repress pro-inflammatory gene
expression [414]. Numerous transcriptional targets of GR inhibit cytokine release, and GR itself
has the capacity to transrepress NF-κB activity [382,383,415] making GR activation a powerful
way to resolve inflammation. For that reason, dexamethasone (DEX), a synthetic ligand of GR,
has been routinely used as an anti-inflammatory, immunosuppressive agent in the treatment of
IBD [416]. Chronic exposure to stress and frequent GC release results in various adverse side
effects such as osteoporosis, central adiposity, diabetes, hypertension, dyslipidemia, GI diseases
and neurodegeneration [417–420]. Stress is also one of the most significant risk factors for development
of irritable bowel syndrome [421–423]. Furthermore, a deficient or blunted HPA axis is commonly
observed in the clinic in a wide range of autoimmune and inflammatory diseases [424–426].
In the intestine, GCs impact nutrient absorption by modulating expression of digesting enzymes [427],
and enhance glucose uptake by stimulating gene expression of glucose transporters [428,429].
In coordination with the microbiota, they regulate gut ontogeny [427], play a role in the differentiation
of the IEC, regulate the expression of tight junction proteins and thus, maintain the intestinal
epithelial barrier [430,431]. GR is capable of antagonizing TNF-α-induced increase in MLCK protein
expression, a key process mediating the TNF-α increase in intestinal tight junction permeability
during inflammation [430]. Thus, GCs released during stress may have a gastroprotective action [432].
It has been shown that creating a lesion in the hypothalamic PVN or administration of antiserum of
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ACTH inhibits increases in corticosterone and induces gastric erosions provoked by cold-restraint as
well as water and immersion-restraint stress; corticosterone replacement was able to prevent these
malfunctions [432].
In the CNS, GR is implicated in both short- and long-term adaptations in response to stressors
and participates in brain structural and physiological changes after stress exposure [433–435].
GR regulates the expression of genes related to neuronal and glial metabolism, neuronal plasticity
and neurotransmission, and mediates gap junction intercellular communication in neural progenitor
cells [436–438]. Stress-activated GR in microglia triggers changes in cell morphology and increases
the production and release of inflammatory cytokines, switching from brain surveillance function to
eliciting unfavorable effects on neural function and behavior [439–441]. Chronic stress and prolonged
GC exposure have profound effects on emotion and cognition. It leads to maladaptive neuronal and
glial plasticity, changes brain microglia morphology resulting in neuropsychiatric disorders such as
affective, behavioral, and cognitive syndromes including depression, mood imbalance, increased
fear conditioning and anxiety [433,441–445]. Adult rats raised by interactive mothers with high
licking and grooming behavior, compared animals fed and groomed by less interactive females,
show increased hippocampal GR expression, reduced HPA activation and less fear behaviors in
response to acute stress [446–448]. Over-activity of the HPA axis is characterized by elevated levels of
cortisol and disruption of GCs’ negative-feedback and is commonly associated with depression and
post-traumatic stress disorder (PTSD) [449,450]. Methylation of the GR gene promoter, which impacts
circulating cortisol levels, is negatively associated with severity of PTSD and correlates with specific
responses to stress [451]. Moreover, individuals with major mental illness, who often exhibit
hypercortisolemia, may have downregulated levels of GR mRNA. For instance, GR mRNA levels are
reduced in parts of the cortex of patients suffering from depression, bipolar disorder, and schizophrenia.
Furthermore, schizophrenia and bipolar disorder are associated with low GR mRNA levels in parts of
the hippocampus [452].
Several studies indicate an impact of stress, GCs and GR on the gut microbiota. Different types
of psychological stressors including chronic social defeat, restraint conditions, crowding, heat stress,
and acoustic stress can alter the composition of the GI flora [453–458]. Stress induces gut permeability
enabling bacteria and bacterial antigens to cross the epithelial barrier, which can activate a mucosal
immune response with impact on the microbiota composition [19–21]. Importantly, in lean female
mice, stress exposure modifies the microbiota composition to resemble that of obese mice [459].
Maternal separation of rat pups elicits alteration of the fecal microbiota, intestinal dysbiosis, and alters
the HPA axis and colonic cholinergic neural regulation [18,456]. Early life stress increases visceral
sensation, plasma corticosterone and systemic immune response in the stressed animals after an
LPS challenge [18]. Exposure to DEX both acutely (10 days) or chronically (over 4 weeks) in
mice leads to substantial shifts in gut microbiota accompanied by a significant downregulation
of colonic mucin 2 gene expression. Importantly, DEX treatment affects mucin expression only
in specific-pathogen-free (SPF) but not GF mice. Thus, DEX alone is not sufficient to regulate
mucin synthesis in the absence of gut microbes [460]. Moreover, a single high-dose injection of
DEX increased the number of ileal anaerobic bacteria, while low-dose GC resulted in an increase in
coliform bacteria [461]. These alterations in gut bacteria regulate the inflammatory state in a genetically
susceptible mouse model of colitis, demonstrating a gut microbe-mediated mechanism by which
GCs exert their anti-inflammatory effects in the colon. Thus, GC signaling partly mediates its effects
through gut microbes.
Reciprocally, the gut microbiota also mediates stress responses, which is supported by the fact
that an altered gut microbiota can lead to substantial shifts in the HPA axis response to stress [462].
Along a similar line of thought, GF mice present both a reduced anxiety phenotype and disturbed
hypothalamic–pituitary–adrenal (HPA) axis [8,41–43]. However, in GF mice a mild restraint stress
induces an excessive HPA response and higher plasma ACTH and corticosterone levels compared to
the SPF controls, which can be partially reversed by colonizing the GF mice with the flora from SPF
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animals or with only Bifidobacterium infantis [43]. In contrast, reconstitution with the enteropathogenic
Escherichia coli, but not with its mutant strain deprived of the translocated intimin receptor gene,
enhances the response to stress even further, implying that commensal microbiota can affect the
postnatal development of the HPA stress response in mice [43]. In another study using the forced
swim test, 28 day long administration of Lactobacillus rhamnosus (JB-1) produced animals with lower
levels of stress-induced corticosterone and reduced depressive and anxious behavior phenotypes [45].
This outcome was abolished with vagotomy, demonstrating that functional gut to brain direct nerve
signaling is necessary for mediating stress response [45]. The HPA axis response to acute stress
can also be attenuated by treatment with Lactobacillus farciminis [463]. Administration of a probiotic
combination of L. helveticus R0052 and B. longum R0175 reduced anxiety-like behavior in rats and
alleviated psychological distress in volunteers [44]. Moreover, administration of the prebiotics
fructooligosaccharide (FOS) and galactooligosaccharide (GOS) abolished the corticosterone response to
acute swim stress, attenuated anxiety related behavior in naive mice, and anxiety parameters in chronic
social defeat [464]. Delivery of two strains of Lactobacillus species to mice pups ameliorated maternal
separation-induced gut functional abnormalities and reduced bacterial adhesion and penetration into
the colonic mucosa. Moreover, probiotic treatment improved gut dysfunction induced by maternal
separation, at least in part by reducing the elevated corticosterone levels and by normalizing the activity
of the HPA axis [465]. Thus, adequate stress response of the host depends on microbiota-regulated
metabolism of GCs.
3.5.2. Mineralocorticoid Receptor
The MR shows an affinity for MCs like aldosterone, its precursor deoxycorticosterone, as well as
for GCs. MCs are a class of steroids produced in the adrenal cortex which mainly influence electrolyte
and fluid balance, hemodynamic homeostasis and tissue repair. MR is expressed in many tissues such
as the kidney, colon, heart, CNS, adipose tissue, macrophages and sweat glands [466]. In the brain, MR
is largely restricted to neurons in limbic areas such as the hippocampus and amygdala [368,467,468].
This contrasts with the GR, which is expressed throughout the brain [368]. The hormones estrogen [469]
and progesterone [470], and the nuclear receptors GR, MR, and their MR:GR heterodimer can
activate MR gene transcription [471]. The promoter of the MR gene also contains a noncanonical
cAMP-responsive element, which for instance allows GPR48 stimulation of MR expression through
the cAMP/PKA pathway [472]. The MR gene can generate several transcripts [473], which in humans
are derived from two different promoters [471,474]. GR and MR are co-expressed in many types of
tissues, often in the same cells, where they interact at the molecular and functional levels, in synergy,
but sometimes also in antagonism. GR and MR can coordinate their actions, for example in regulating
neuronal Ca2+ voltage-gated currents in the hippocampus [475–477]. In preadipocytes, selective MR
activation results in the transcription of several genes, including Pparγ required for preadipocyte
maturation. On the contrary, GR agonists prevent adipogenesis [478,479]. Moreover, in response to
inflammation GR often dampens MR’s effects. Overstimulation of MR in the heart, vessels, kidneys,
and parts of the brain may lead to increased reactive oxygen species, inflammation, and cardiovascular
and renal diseases [480]. Thus, balanced MR and GR activities are crucial for adaptation to stimuli
and homeostasis [481,482]. The DNA binding domains of MR and GR are nearly identical, and both
receptors are capable of binding GREs as well as nGREs [483,484]. Besides competing for the same
ligands MR and GR share several co-regulatory proteins required for the initiation of transcription.
However, the primary functions of MR and GR and some of their ligands serve different purposes
and are regulated very differently [485,486]. A fundamental role of MR includes the regulation of
ion and fluid transport in order to sustain osmotic and hemodynamic homeostasis, maintenance
of membrane excitability in neurons and muscle cells as well as responses to injury. MR regulates
blood pressure, and its inappropriate activation leads to hypertension [487–489]. Treatment with MR
antagonists decreases both cardiovascular risk markers and insulin resistance [487–490]. Accordingly,
bacterially-derived GC metabolites have been suggested to cause hypertension [360]. Besides acting as
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a typical NR and modulating gene expression, MR displays several rapid nongenomic activities which
do not require transcription and are mediated by classical cell signaling pathways [491–494]. The types
of nongenomic signaling mediated by MR vary between different cells and depend on the activating
stimuli. Typically, it includes protein kinase C (PKC), cyclic adenosine 3′,5′-monophosphate (cAMP)
and phosphoinositide 3-kinases (PI3K), cumulating with downstream activation of various kinases,
ion channels and pumps [491–494]. MR also acts through the EGF–EGFR–MEK1/2–ERK1/2 signaling
cascade which influences cell differentiation, proliferation and repair [492,495,496]. In various tissues,
nongenomic MR activation leads to intracellular Ca2+ flux [497].
MR exhibits different ligand preferences depending on the tissues: aldosterone in the kidney
and colon epithelia, and GCs in most parts of the brain. In most tissues at basal levels, GCs favors
binding to MR. For instance, in the hippocampus MRs bind GCs with approximately 10-fold higher
affinity than its colocalized GR. When GCs levels rise due to stress or circadian cycle GCs also activate
GR [366,368,498–500]. Thus, GR is thought to be responsible for the GCs-triggered stress response.
However, MR located at the plasma membrane has been shown to also mediate stress level GC
effects in a nongenomic manner in the hippocampus [501]. In the brain, GCs are more abundant
than aldosterone, thus they constantly occupy MR. GCs are able to passively diffuse across the
plasma membrane, and their bioavailability within the cell is controlled by two 11β-hydroxysteroid
dehydrogenase enzymes. 11β-hydroxysteroid dehydrogenase-2 (11β-HSD2) converts cortisol and
corticosterone to the inactive cortisone, and 11β-hydroxysteroid dehydrogenase-1 (11β-HSD1) converts
cortisone back to its active form [502,503]. The two 11β-HSD enzymes show cell-specific expression,
therefore controlling the level of active GCs and in turn receptor activation. 11β-HSD2 is expressed in
aldosterone-sensitive tissues, including kidneys, liver, lungs, colon, salivary glands, H2D2 neurons
and placenta, while 11β-HSD1 is highly expressed in key metabolic tissues like liver, adipose tissue,
and CNS. Inactivation of GCs by 11β-HSD2 allows binding of aldosterone to the MR within aldosterone
target cells, and at the same time, limits activation of the GR in these cells [504–506]. 11β-HSD1
plays an important role in switching between MR-mediated proinflammatory activation of IL-6,
TNF-α and NF-κB and GR-triggered suppression of these factors in microglial cells [507]. Thus,
this enzyme mediates activation of microglia and may affect the development of neurogenerative
diseases. Remarkably, the microbiota is able to produce glycerrhetinic acid-like factors (GALFs),
named after glycerrhetinic acid from licorice root, which can inhibit 11β-HSDs activity [360]. Therefore,
by modulating the activity of the 11β-HSD enzymes, the microbiota influences whether MR or GR
is activated.
Appropriate activation of the MR is essential for normal neuronal differentiation, migration,
and function of the developing and adult brain [508–511]. Chronic social stress in adolescent
mice evokes a decrease in the mRNA levels of MR and GR in the hippocampus. It also increases
adrenal weight, elevates GCs levels, dampens the circadian rhythm and promotes anxiety-related
behaviors compared to unstressed mice. The decrease in MR expression and behavioral changes
are still detectable a year later, suggesting underlying epigenetic events [512]. Subjects suffering
from depression and bipolar disorder display reduced total MR and increased ratio of MR to GR
mRNA expression in the prefrontal and anterior cingulate cortex. On the contrary, a decreased MR
to GR ratio for both mRNA and receptor is seen in the dorsolateral prefrontal cortex and PVN [513].
Moreover, chronic treatment with corticosterone triggers a depression-like phenotype in mice, however,
co-administration of a MR-specific antagonist, spironolactone, mitigates depressive behavior [514].
Both MR and GR participate in corticosteroid-induced direct transcriptional repression of the 5-HT1A
gene [483]. Physiological effects of 5-HT1A receptor agonists are attenuated after chronic treatment
with GCs [515,516]. Therefore, both receptors influence behavior and impact depression [445,517,518].
The hippocampus, which shows the highest expression of MR in the brain, is the major integrative
center for the formation of memories, learning, cognition, and coping with stress. In fact, MR activity
is crucial for learning and for forming memories. MR antagonists boost cognition in heart failure
patients, sometimes without an actual impact on cardiac function [519] while the decrease in MR
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expression in the aged hippocampus positively correlates with age-induced impairments in spatial
memory [520]. However, for optimal cognitive performance, balanced activation of both MR and GR
is required [521]. Interestingly, therapy with the antidepressant amitriptyline in young rats increases
hippocampal MR but not GR expression, and stimulates spatial memory. The same treatment has no
effect in aged rats [522]. Furthermore, long-term treatment with amitriptyline in middle-aged rats
prevented the prevalence of cognitive impairments and reduced anxiety-related behaviors in aged
rats [523]. In contrast, short-term use of MR antagonists in healthy humans has adverse effects on
attention, memory, and cognition [524].
In summary, the microbiota modulates levels of GCs thereby affecting activity of GR and MR in
multiple organs including the brain (Figure 3).
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Figure 3. Interaction between glucocorticoid receptor (GR), mineralocorticoid receptor (MR) and
microbiota. By regulating the activity of 11β-HSD, bacterial glycerrhetinic acid-like factors (GALFs)
modulate GCs availability and GCs affinity towards GR or MR. Additionally, the microbiota regulates
circadian production of GCs in the intestine thereby affecting the activity of steroid receptors in
multiple tissues.
3.5.3. Estrogen Receptors
Estrogens are primarily produced in the ovaries, adrenal glands and adipose tissue and
are C-18 steroid hormones derived from the reduction of C-27 cholesterol. The main forms of
endogenous estrogens are estradiol (E2), which is predominant in nonpregnant women prior to
menopause; estrone (E1), present after menopause; and estriol (E3), abundant during pregnancy [525].
While passing through the liver E1 and E2 estrogens undergo irreversible hydroxylation at the C-2,
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C-4, or C-16 positions of the steroid ring. These modifications produce estrogen metabolites varying in
hormone potency and half-life. The types of estrogen and their modifications influence their preference
for and capacity to activate different types of estrogen receptors (ERs) [526].
Estrogens mainly play role in reproduction, however, they are also vital modulators of metabolism
and behavior. They protect against high-fat diet induced insulin resistance and glucose intolerance in
mice [527]. Lower levels of estrogens in postmenopausal women [528] or in ovariectomized animals
are associated with obesity [529], while estradiol-17β replacement in ovariectomized mice prevents
weight gain by diminishing food intake and stimulating energy expenditure [529]. Accordingly,
hormone replacement therapy in postmenopausal women reverses the progression of obesity and
metabolic dysfunctions [530]. Importantly, estrogen levels strongly impact gut microbiota composition
and microbiota affects body weight. In men and postmenopausal women, levels of total urinary
estrogens correlate to richness and α diversity of fecal microbiota [531,532]. Ovariectomy in adult mice
diminishes gut microbiota richness [533]. In rats, neonatal androgenization or adult ovariectomy causes
shifts in the relative abundances of the two major phyla causing a higher Firmicutes to Bacteroidetes
ratio [533]. In humans, similar gender-dependent differences were observed. Estrogens are strongly
and significantly associated with the fecal Clostridia taxa, including non-Clostridiales and three genera
in the Ruminococcaceae family [531], while men have higher levels of Bacteroidetes and Prevotella than
women [534,535]. In mice, sex differences in gut microbiota are decreased after castration of male
mice [536]. Stunningly, hormonal changes caused by early androgenisation or ovariectomy impact the
microbial flora more strongly than nutritional changes from chow to a high fat diet [533], suggesting a
decisive role for gonadal hormone levels in the modulation of GI flora.
A cluster of bacteria, referred to as “estrobolome” due to its capacity to metabolize estrogens,
can significantly influence the host’s estrogen levels [537]. The series of reductive reactions leading
to the synthesis of estrogens from cholesterol is partly catalyzed by hydroxysteroid dehydrogenases
(HSD), a group of alcohol oxidoreductases. Bioinformatic annotation of HSD in all entirely sequenced
bacterial genomes has proven that HSDs are found in a wide variety of microorganisms including
bacteria and archaea. A large number of HSD-expressing bacteria participate in the normal human gut
microbiota [538].
After circulation in the blood, estrogens and their metabolites are directed to the liver where
they are conjugated through glucuronidation or sulfonation which facilitates their excretion in the
bile, urine and feces [539]. β-glucuronidases and β-glucosidases, expressed by several bacterial
strains, are capable of deconjugating estrogen which can then be reabsorbed by the intestine and
reenter the host’s estrogen pool [540,541]. The activity of fecal bacterial β-glucuronidase activity,
just like the intestinal flora composition, can be modulated by diet [542–544]. In rats, a decrease in
fecal β-glucuronidase enzyme activity was observed after antibiotics administration [545]. In line
with this observation, antibiotic therapy results in significant increases in fecal conjugated estrogens
and a reduction in urinary estrogen in men and women [546–548]. More than half of the low
G + C% gram-positive Firmicutes, which are a dominant bacterial group within the human large
intestine [549], harbor β-glucosidase activity [550]. Most of Bacteroides spp. carry high β-glucuronidase
and β-glucosidase activity, while the majority of Bifidobacterium spp. show only β-glucuronidase
activity. The highest β-glucuronidase and β-glucosidase activities in feces correlate with the occurrence
of Clostridium spp. [540,550,551]. Similarly, Peptococcus niger by means of sulfatase activity can
deconjugate estrogen sulfate metabolites [552]. Furthermore, the gut microbiota is able to metabolize
estrogen-like compounds from nutrition. For instance, daidzein found in soy can be metabolized to
O-desmethylangolesin (ODMA) and S-equol [553], which are structurally similar to estrogen and can
activate ER [554,555]. It is noteworthy that individuals harboring a gut flora capable of producing
ODMA, but not S-equol, are more likely to be obese [553]. Importantly, several epidemiologic
studies have suggested a possible association of antibiotic use and breast cancer risk which may
be a consequence of disturbed estrogen metabolism [556,557].
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Microbiota-derived estrogen may influence the host’s fertility. In GF mice, reproduction capacity is
lower than in SPF mice. Inoculation of GF mice with B. distasonis and C. perfringens induces significant
increase in sperm motility in male mice while in females it results in the normalization of the estrous
cycle, and rises the copulation and fertilized egg implantation rates. On the contrary, the reproduction
rate of mice carrying only the single Bacillus subtilis strain is comparable to GF mice, underscoring the
importance for hormonal homeostasis of selected bacterial strains in the gut [558].
Estrogen exerts its activity via the estrogen receptor α (ERα, NR3A1) and β (ERβ, NR3A2) [559,560].
ERα and ERβ are highly homologous, particularly in the DNA binding domains (95%) and the ligand
binding domain (55%), and show affinity for the same estrogen response elements (ERE) in DNA [560].
Although ERα and ERβ share similar ligand binding domains, ERβ possesses a relative binding
affinity for several steroid hormones that differs from that of ERα [561]. ERα and ERβ are expressed in
multiple organs [562] including all parts of the GI tract [563–566], but their expression levels differs
in various tissues. For instance, ERα is the predominant isotype in the breast and uterus, whereas
ERβ is expressed at higher levels in the urogenital tract, endothelial cells and the CNS [562,567].
ERα and ERβ are present throughout the rostral–caudal extent of the brain and spinal cord and their
expression overlaps in most of the CNS with a few exceptions. For instance, although both receptors
are expressed by neurons in the arcuate nucleus and hippocampus, ERα is more abundant in the
arcuate nucleus, and ERβ is more prevalent in the hippocampus [568–572]. Importantly, ERβ mediates
brain development by regulating neural progenitor cell proliferation [573] and stem cell differentiation
into dopamine neurons [574].
ERα, but not ERβ, is vital to reproductive function and regulation of the preovulatory surge
of luteinizing hormone (LH) in response to rising levels of estrogen [575–577]. However, ERβ may
be involved in mediating the negative feedback control of anterior pituitary LH secretion, a process
mainly governed by ERα [578]. Moreover, ERα-null female mice are deficient in sexual behavioral
interactions, they are more aggressive towards other females and show reduced levels of parental
behavior towards newborn pups [575]. Thus, ERα regulates reproduction not only at the physiological,
but also behavioral level.
The effects of estrogens on energy balance are primarily mediated by ERα, as women or female
mice with mutations in the ERα gene display hyperadiposity [579,580]. Importantly, estrogen levels
directly affect nutrient uptake from the intestine [581,582]. Female mice lacking ERα in hypothalamic
steroidogenic factor-1 (SF1) neurons are characterized by hypometabolism and abdominal obesity,
but not hyperphagia. In contrast, loss of ERα from the hypothalamic POMC neurons leads to
hyperphagia, without directly influencing energy expenditure or fat distribution [583]. Thus, estrogens
act on distinct hypothalamic ERα neurons to regulate different aspects of energy homeostasis
and reproduction.
While ERα is essential for reproductive neuroendocrine function, ERβ seems more important
for emotional behavior. ERβ-null mice show increases of 5-HT1A receptor expression in the
medial amygdala as well as lower serotonin and dopamine levels in several brain regions [584,585].
Accordingly, E2, acting via ERβ located in 5-HT cell bodies of the dorsal raphe nucleus, induces
expression of tryptophan hydroxylase which is involved in the synthesis of 5-HT [586]. As a result,
mice and rats treated with E2 or selective ERβ agonists and subsequently submitted to the forced
swim test, spend less time immobile and struggle longer than non-treated controls, which is interpreted
as a less depressive-like behavior [587,588]. This effect is not observed in ERβ-null mice [587]. Selective
agonists of ERβ exert potent anxiolytic activity in rats [589,590], whereas ERβ-null mice show increased
anxiety accompanied by reduced threshold for the induction of synaptic plasticity in the basolateral
amygdala [584,585]. In elevated plus maze and open field tests for anxiety-like behaviors, ERβ-null
mice show increased anxiety relative to their wild-type counterparts. Importantly, this phenotype
of the ERβ-null mice is present only in females, indicating a specific gender-dependent sensitivity
to hormonal changes expressed in behavior [584,585]. ERβ may exert its impact on behavior via
the HPA axis [591] and other behavior-related hormones as it represses neuronal vasopressin [592],
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CRH [593] and corticosterone [590]. Notably, GCs are transported in the blood predominantly bound
to corticosteroid-binding globulin (CBG), also known as transcortin, which serves as a regulator of
the biological availability of GCs. CBG is produced by the liver, and interestingly, it is stimulated by
estrogens, which is reflected as higher levels of total circulating corticosterone in females compared
to males [594]. Importantly, the sex hormones estrogen and progesterone influence the expression
of MR [469,470] and the ER inhibits the transactivational effects of the MR in several cell types [595].
In addition to MCs and GCs, progesterone is a competitive MR antagonist with a similar affinity for
the MR as aldosterone [596]. Moreover, MR mRNA levels in the human hippocampus show higher
concentrations in women compared to men [597]. The hormonal differences associated with MR
correlate with occurrence of cardiovascular diseases in premenopausal woman. Consistently, sex
differences exist in the cortisol stress response [598], in response to parental separation of pups [599],
in hippocampal MR and GR expression after exposure to stress of adults rats [600,601] and in the
prevalence of stress-related psychiatric disorders [602,603]. On the contrary, DEX-treated female
rats increase ERβ expression in the hypothalamic PVN and supraoptic nuclei (SON) [604], whereas
adrenalectomy reduces ERβ mRNA expression in the PVN, and corticosterone replacement fully
reverses this effect in a dose-dependent fashion [605]. Thus, ERβ mediates and interacts with the
HPA axis.
In contrast, treatment with the ERα agonist propylpyrazoletriol (PPT) was anxiogenic in the
elevated plus maze test and, in a consistent manner, stimulated corticosterone stress hormone
response [590,593]. These results provide an explanation to the fact that estrogen has both anxiogenic
and anxiolytic effects [606,607].
Considering the vital contribution of estrogens to the regulation of fertility, metabolism and
behavior described above, the regulation of estrogen bioavailability by the microbiota impacts essential
functions in the host’s life.
3.6. Thyroid Hormone Receptors
An essential component of thyroid hormones (TH), iodide is actively transported and concentrated
in the thyroid gland and incorporated in THs. Thyroid cells combine iodine and the amino acid
tyrosine to make T3 and T4 [608–611]. Thyroxine (T4) contains four iodine atoms and the more potent
triiodothyronine (T3) has three of them. T4 is the prevalent form of released THs and deiodination of
its outer ring by enzymes iodothyronine deiodinases yields T3. The deiodinases are selenoproteins
expressed in various tissues including the GI tract which regulate the intracellular biological activity
of THs [612–615]. Thus, deficiency of deiodinases can mimic hypothyroidism.
TH secretion is regulated by a negative feedback system involving the hypothalamus, the pituitary
gland and the thyroid gland. Thyrotropin releasing hormone (TRH) is synthetized in the hypothalamus
and when released it is transported in the circulation and binds to receptors of the pituitary thyrotropes.
The pituitary then secretes thyroid stimulating hormone (TSH) which promotes TH release from the
thyroid gland. Both TRH and TSH secretions are negatively regulated by TH. Also, somatostatin
and dopamine inhibit TSH release [616,617]. Importantly, both of these factors can be produced by
microbiota [35,48,49].
THs serve as ligands for the thyroid hormone receptors α (TRα, NR1A1) and β (TRβ, NR1A2),
which occur in several forms. TR-α1 is widely expressed with high levels in cardiac and skeletal
muscles. In the brain its highest levels are in the olfactory bulb, hippocampus and parts of cerebellar
cortex. TR-α2 is most abundant in the brain but it is the only TR form that is not capable of binding
thyroid hormone. TR-β1 is present mainly in brain, liver and kidney and TR-β2 is limited to brain with
high levels in the hypothalamic PVN and anterior pituitary [618,619]. TR can bind to DNA whether or
not it is activated by appropriate ligands. In the unliganded inactivated from it recruits corepressors
thereby inhibiting gene expression. Upon ligand binding, the TR changes conformation facilitating
dissociation of the corepressors and the recruitment of coactivators resulting in the stimulation of
target gene promoters and gene transcription [620]. TRs also exerts nongenomic actions [621].
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T3 increases cardiac output and heart rate, lung ventilation, basal metabolic rate, catabolism of
proteins and carbohydrates as well as growth and brain development. In the brain, THs promote a wide
range of developmental processes including myelination, neuronal migration as well as neuronal and
ganglion cell differentiation [611,619]. THs also affect mood and behavior [622]. Among target genes
in the brain TH regulates genes coding for brain myelin basic protein [623,624], BDNF [625], glutamine
synthase [626], prostaglandin D2 synthase [627], adhesion molecules, matrix proteins, factors affecting
neuronal migration and apoptosis, nerve metabolism and signal transduction [628–630]. Both TH
deficiency and excessive production lead to metabolic and neuronal malfunctions. Hyperthyroidism is
characterized by increased levels of free circulating TH, weight loss, frequent bowel movements and
associated diarrhea, weakness, tremors, difficulty to sleep, heat intolerance, increased heartbeat,
anxiety, and memory problems. Hypothyroidism is associated with weight gain, exhaustion,
constipation, indigestion, depression, anxiety, psychosis, general pains and fertility problems in
females [619,631–633]. Hypothyroidism affects brain development and may cause neurological
defects including diminished neuron development in hippocampus, cerebral cortex, visual and
auditory cortex [628,634,635]. Hypothyroidism-caused developmental malfunctions can be reversed
if THs are administrated within 2 weeks after birth [628]. On the contrary, absence of congenital
hypothyroidism treatment in infants leads to a profound brain development delay accompanied by
mental retardation. Interestingly, hypothyroid patients show lower amounts of gut Bifidobacterium and
Lactobacilli while having more Enterococci than healthy subjects [636]. Additionally, patients with a
history of hypothyroidism show more prevalent occurrence of small intestine bacterial overgrowth
(SIBO) which may be reversed by antibiotic treatment [637].
Hypothyroidism may be due to genetic factors or dietary iodine deficiency. Iodine concentration
in the thyroid gland as well as in peripheral tissues largely depends on ionic pumps and transporters,
the efficiency of which is modulated by iodothyronine deiodinases as well as the availability of
iodine and selenium. An inability to synthesize TH results in a decrease of the negative feedback to
hypothalamus, which stimulates TSH production leading to enlargement of thyroid gland, a condition
named goiter. An enlarged thyroid gland enhances its ability to trap iodine [638–640].
The amount of exchangeable T3 and T4 in the intestine constitutes the second largest reservoir
of TH after the thyroid gland, before the liver and kidneys [641]. Short gut syndrome and bariatric
surgery are both associated with reduced intestinal nutrient uptake and malnourishment, which do not
influence iodine levels [642,643]. On the contrary, modulation of rat microbiota by kanamycin reduces
iodine uptake [644] implying that the gut flora constitutes the functional component of the GI tract
responsible for iodine absorption. Moreover, the microbiota in the small intestine, cecum, colon and
feces of rats reversibly binds T3 and T4 and this capacity is abolished by antibiotic treatment [645,646].
Ex vivo studies show that Escherichia coli, one of major gut colonizers, is capable of binding T3 and
T4 [647]. Thus, gut flora could serve as a reservoir, retaining and releasing TH.
Selenium is an essential microelement required for the synthesis and bioactivity of selenoproteins,
including deiodinases. Consequently, this microelement affects the activity of TH. Selenium is
absorbed in the duodenum and caecum [648] and in the body is most highly concentrated in the
thyroid gland [649]. Gut bacteria also require selenium and when it is not taken up by the host,
colonic bacteria utilize it [650]. Upon selenium shortage, the microbiota gets to the point of competing
with the host for selenium [651], which may result in reduced expression of selenoproteins in the
host [652] and the microbiota may inhibit the enzymatic activity of deiodinases in the cecum and colon
walls [653]. Selenium supplementation results in increased diversity of gut bacterial population [652]
and enhanced colonic and rectal fermentation [654] as multiple microbes are capable of producing
their own selenoproteins [655–658].
THs are inactivated mainly in the liver by conjugation. Attached sulfate and glucuronic acid
moieties enable secretion of the conjugated hormones in bile and decrease their reabsorption from
the intestine. Moreover, sulfation facilitates irreversible deiodination and catabolism of THs [659].
However, glucuronidated and sulfated THs can be hydrolyzed to active precursors in the GI tract
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and various other tissues. Thus, conjugated THs can serve as a reservoir for active hormones. In rats,
but not humans, stimulation of glucuronidation by drugs and toxins may results in a drop in T4 and T3
levels provoking elevated TSH secretion and resulting in goiter formation [638,660,661]. Incubation of
various TH sulfate conjugates with human or rat feces results in complete hydrolysis of the conjugates.
However, preheated fecal suspensions and supernatants of centrifuged fecal solution do not affect
sulfation of TH. Similarly, fecal suspension obtained from GF or ampicillin-treated rats showed
drastically reduced deconjugation capacity [662–664]. Consequently, in GF mice the enterohepatic
cycle of TH including intestinal deconjugation of T3 secreted in bile and its reabsorption to circulation
is abolished [665]. Deconjugation activity relies on the presence of obligate anaerobic intestinal bacteria.
Bacterial strains isolated from human feces, including Peptostreptococcus productus, possess sulfatase
activity [662–664].
The bacterial signaling that influences TH turnover and LPS which triggers septic shock also
promotes non-thyroidal illness syndrome. Higher doses of LPS in mice decrease the levels of liver
deiodinase mRNA, pituitary TR mRNA and protein, and reduces the amount of TSH receptor mRNA
in the thyroid gland [666]. In pigs, LPS lowers TH levels in serum and most tissues. Moreover,
it decreases the expression of deiodinases in the liver and kidneys as well as deiodinases activity in
kidneys. LPS administration results in lowered mRNA levels of TRβ in the frontal lobe, adrenal glands
and kidney cortex [667]. Thus, bacterial LPS is capable of affecting TH signaling on multiple levels in
the whole organism, including in the brain.
Patients suffering from celiac disease, which is generally accompanied by GI inflammation
and abnormal microbiota, show malabsorption of orally delivered T4 and in case of Hashimoto
thyroiditis require higher doses of the T4 drugs [668]. Approximately one third of patients with
autoimmune thyroid disease show also symptoms of atrophic gastritis [669]. Furthermore, 40% of
Hashimoto thyroiditis patients exhibit lymphocytic colitis [670]. Rarefication and partial disappearance
of microvilli, spaces between microvilli and thickening of microvilli were increased in intestinal
mucosal biopsies from autoimmune thyroiditis patients. The patients also showed increased mucosal
permeability [671]. Thus the host’s TH affects gut health and therefore also the gut flora. TH can
also affect the bacteria population by influencing the number of parietal cells in the gastric mucosa,
the secretion of pepsinogen and the basal acidity in the stomach [672,673]. Thereby in the stomach,
TH increases the efficiency of killing bacteria taken up with the food, reducing the colonization of
more distal parts of the GI tract by these foodborne microorganisms.
The direct connection of enteric bacteria and TR in the context of the gut–brain axis has not been
addressed so far. However as seen above, the importance of TR in brain development and proper
functioning and the crucial impact of the microbiota on TR ligands availability, provide strong support
for a GI tract–CNS TR-dependent signaling.
4. Conclusions and Future Directions
As presented in this review, there are multiple studies proving the connection between a healthy
gut and a healthy brain. NRs are key players in regulating virtually every process necessary for the
survival and health of a living organism. By influencing NRs, gut flora participates in the regulatory
roles of the nuclear receptors (Figure 4). Via signaling to the brain, the microbiota regulates metabolism,
CNS development, inflammation as well as mood and behavior. Notably, it also impacts reproductive
behavior and, therefore, contributes to species survival. Importantly, the human host has the capacity
to voluntarily influence and improve its own microbiota by the power of nutritional or probiotic
interventions. Thus, nutritional approaches, combined with physical exercise, aiming at providing or
sustaining the production of NR ligands and increasing the microbiota diversity should appear as a
common sense approach to promote a physically and physiologically healthy life.
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